171 related articles for article (PubMed ID: 31502400)
21. iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study.
Mcaddy NC; Saffar H; Litière S; Jespers P; Schöffski P; Messiou C
Cancer Imaging; 2020 Oct; 20(1):79. PubMed ID: 33121537
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.
Hindi N; Razak A; Rosenbaum E; Jonczak E; Hamacher R; Rutkowski P; Bhadri VA; Skryd A; Brahmi M; Alshibany A; Jagodzinska-Mucha P; Bauer S; Connolly E; Gelderblom H; Boye K; Henon C; Bae S; Bogefors K; Vincenzi B; Martinez-Trufero J; Lopez-Martin JA; Redondo A; Valverde C; Blay JY; Moura DS; Gutierrez A; Tap W; Martin-Broto J
ESMO Open; 2023 Dec; 8(6):102045. PubMed ID: 38016251
[TBL] [Abstract][Full Text] [Related]
23. Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022.
Wilky BA; Maleddu A
Clin Cancer Res; 2023 Apr; 29(7):1163-1166. PubMed ID: 36692840
[TBL] [Abstract][Full Text] [Related]
24. Advanced alveolar soft part sarcoma responds to apatinib.
Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C
Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.
Stacchiotti S; Negri T; Zaffaroni N; Palassini E; Morosi C; Brich S; Conca E; Bozzi F; Cassinelli G; Gronchi A; Casali PG; Pilotti S
Ann Oncol; 2011 Jul; 22(7):1682-1690. PubMed ID: 21242589
[TBL] [Abstract][Full Text] [Related]
26. Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups.
Orbach D; Brennan B; Casanova M; Bergeron C; Mosseri V; Francotte N; Van Noesel M; Rey A; Bisogno G; Pierron G; Ferrari A
Pediatr Blood Cancer; 2013 Nov; 60(11):1826-32. PubMed ID: 23857870
[TBL] [Abstract][Full Text] [Related]
27. Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma.
Castelli C; Tazzari M; Negri T; Vergani B; Rivoltini L; Stacchiotti S; Pilotti S
J Transl Med; 2013 Sep; 11():237. PubMed ID: 24074204
[TBL] [Abstract][Full Text] [Related]
28. Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005).
Brennan B; Zanetti I; Orbach D; Gallego S; Francotte N; Van Noesel M; Kelsey A; Casanova M; De Salvo GL; Bisogno G; Ferrari A
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286582
[TBL] [Abstract][Full Text] [Related]
29. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
30. Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study.
Fujiwara T; Nakata E; Kunisada T; Ozaki T; Kawai A
BMC Cancer; 2022 Aug; 22(1):891. PubMed ID: 35971085
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
Chen E; Jonker D; Gauthier I; MacLean M; Wells J; Powers J; Seymour L
Clin Cancer Res; 2009 Feb; 15(4):1481-6. PubMed ID: 19228749
[TBL] [Abstract][Full Text] [Related]
32. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
33. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
[TBL] [Abstract][Full Text] [Related]
34. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
[TBL] [Abstract][Full Text] [Related]
35. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.
Schuetze SM; Bolejack V; Choy E; Ganjoo KN; Staddon AP; Chow WA; Tawbi HA; Samuels BL; Patel SR; von Mehren M; D'Amato G; Leu KM; Loeb DM; Forscher CA; Milhem MM; Rushing DA; Lucas DR; Chugh R; Reinke DK; Baker LH
Cancer; 2017 Jan; 123(1):90-97. PubMed ID: 27696380
[TBL] [Abstract][Full Text] [Related]
37. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
[TBL] [Abstract][Full Text] [Related]
38. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.
Alberts SR; Fitch TR; Kim GP; Morlan BW; Dakhil SR; Gross HM; Nair S
Am J Clin Oncol; 2012 Aug; 35(4):329-33. PubMed ID: 21422991
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
[TBL] [Abstract][Full Text] [Related]
40. Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.
Mir O; Boudou-Rouquette P; Larousserie F; Blanchet B; Babinet A; Anract P; Goldwasser F
Anticancer Drugs; 2012 Aug; 23(7):745-8. PubMed ID: 22331039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
